UnitedHealthcare IV Tocilizumab Coverage Update

Coverage Criteria and Medical Necessity

Polyarticular Juvenile Idiopathic Arthritis

Tocilizumab is proven and medically necessary when ALL of the following are met

PJIA initial therapy: Diagnosis of polyarticular juvenile idiopathic arthritis (PJIA); prescriber attestation that the patient or caregiver are not able to be trained or are physically unable to administer tocilizumab FDA labeled for self-administration (prescriber must submit explanation); tocilizumab dosed according to FDA-labeled dosing for PJIA; patient is not receiving tocilizumab in combination with a systemic targeted immunomodulator (e.g., adalimumab, certolizumab [Cimzia], etanercept [Enbrel], abatacept [Orencia], upadacitinib [Rinvoq], golimumab [Simponi], tofacitinib [Xeljanz/Xeljanz XR]) for treatment of the same indication; prescribed by or in consultation with a rheumatologist; initial authorization is for no more than 12 months.

PJIA continuation: Patient has previously received tocilizumab injection for intravenous infusion; documentation of positive clinical response to tocilizumab; prescriber attestation that the patient or caregiver are not able to be trained or are physically unable to administer tocilizumab FDA labeled for self-administration (prescriber must submit explanation); tocilizumab dosed according to FDA-labeled dosing for PJIA; patient is not receiving tocilizumab in combination with a systemic targeted immunomodulator for treatment of the same indication; authorization is for no more than 12 months.

Rheumatoid Arthritis

Tocilizumab is proven and medically necessary when ALL of the following are met

RA initial therapy: Diagnosis of moderately to severely active rheumatoid arthritis (RA); and one of the following: history of failure or intolerance to a 3-month trial of one non-biologic DMARD at maximally indicated doses unless contraindicated or clinically significant adverse effects occurred; or prior treatment with a systemic targeted immunomodulator FDA-approved for RA (e.g., adalimumab, certolizumab [Cimzia], etanercept [Enbrel], baricitinib [Olumiant], abatacept [Orencia], upadacitinib [Rinvoq], golimumab [Simponi], tofacitinib [Xeljanz/Xeljanz XR]); or patient is currently on tocilizumab; prescriber attestation that the patient or caregiver are not able to be trained or are physically unable to administer tocilizumab FDA labeled for self-administration (prescriber must submit explanation); tocilizumab dosed according to FDA-labeled dosing for RA; patient is not receiving tocilizumab in combination with a systemic targeted immunomodulator for treatment of the same indication; prescribed by or in consultation with a rheumatologist; initial authorization is for no more than 12 months.

RA continuation: Patient has previously received tocilizumab injection for intravenous infusion; documentation of positive clinical response to tocilizumab; prescriber attestation that the patient or caregiver are not able to be trained or are physically unable to administer tocilizumab FDA labeled for self-administration (prescriber must submit explanation); tocilizumab dosed according to FDA-labeled dosing for RA; patient is not receiving tocilizumab in combination with a systemic targeted immunomodulator for treatment of the same indication; authorization is for no more than 12 months.

Systemic Juvenile Idiopathic Arthritis

Tocilizumab is proven and medically necessary when ALL of the following are met

SJIA initial therapy: Diagnosis of systemic juvenile idiopathic arthritis (SJIA); prescriber attestation that the patient or caregiver are not able to be trained or are physically unable to administer tocilizumab FDA labeled for self-administration (prescriber must submit explanation); tocilizumab dosed according to FDA-labeled dosing for SJIA; patient is not receiving tocilizumab in combination with a systemic targeted immunomodulator (e.g., adalimumab, certolizumab [Cimzia], etanercept [Enbrel], abatacept [Orencia], upadacitinib [Rinvoq], golimumab [Simponi], tofacitinib [Xeljanz/Xeljanz XR]) for treatment of the same indication; prescribed by or in consultation with a rheumatologist; initial authorization is for no more than 12 months.

SJIA continuation: Patient has previously received tocilizumab injection for intravenous infusion; documentation of positive clinical response to tocilizumab; prescriber attestation that the patient or caregiver are not able to be trained or are physically unable to administer tocilizumab FDA labeled for self-administration (prescriber must submit explanation); tocilizumab dosed according to FDA-labeled dosing for SJIA; patient is not receiving tocilizumab in combination with a systemic targeted immunomodulator for treatment of the same indication; authorization is for no more than 12 months.

Giant Cell Arteritis

Tocilizumab is proven and medically necessary when ALL of the following are met

GCA initial therapy: Diagnosis of giant cell arteritis (GCA); prescriber attestation that the patient or caregiver are not able to be trained or are physically unable to administer tocilizumab FDA labeled for self-administration (prescriber must submit explanation); tocilizumab dosed according to FDA-labeled dosing for GCA; patient is not receiving tocilizumab in combination with a systemic targeted immunomodulator (e.g., sarilumab [Kevzara], abatacept [Orencia], upadacitinib [Rinvoq]) for treatment of the same indication; prescribed by or in consultation with a rheumatologist; initial authorization is for no more than 12 months.

GCA continuation: Patient has previously received tocilizumab injection for intravenous infusion; documentation of positive clinical response to tocilizumab; prescriber attestation that the patient or caregiver are not able to be trained or are physically unable to administer tocilizumab FDA labeled for self-administration (prescriber must submit explanation); tocilizumab dosed according to FDA-labeled dosing for GCA; patient is not receiving tocilizumab in combination with a systemic targeted immunomodulator for treatment of the same indication; authorization is for no more than 12 months.

Cytokine Release Syndrome

Tocilizumab is proven and medically necessary when ALL of the following are met

CRS initial therapy: Diagnosis of cytokine release syndrome (CRS); patient has received CAR T cell therapy (e.g., tisagenlecleucel, axicabtagene ciloleucel) or CD3-directed therapy (e.g., blinatumomab, teclistamab); tocilizumab is dosed according to FDA-labeled dosing for CRS; initial authorization is for no more than 4 doses.4 doses

CRS continuation: Documentation of positive clinical response; patient continues to experience signs and symptoms of CRS; tocilizumab is dosed according to FDA-labeled dosing for CRS; authorization is for no more than 4 doses.4 doses

Acute Graft-Versus-Host Disease (GVHD)

Tocilizumab is proven and medically necessary when ALL of the following are met

Acute GVHD initial therapy: Diagnosis of steroid-refractory acute graft-versus-host disease (GVHD); and one of the following: patient is receiving tocilizumab in combination with systemic corticosteroids; or patient is intolerant to systemic corticosteroid therapy; initial authorization is for no more than 4 doses.4 doses

Acute GVHD continuation: Documentation of positive clinical response; patient continues to experience acute GVHD; one of the following: patient is receiving tocilizumab in combination with systemic corticosteroids; or patient is intolerant to systemic corticosteroid therapy; authorization is for no more than 4 doses.4 doses

Cytokine Release Syndrome

Covered when ALL of the following are met

CRS initial therapy: Diagnosis of CRS (as appropriate) and tocilizumab dosed per FDA labeled dosing for CRS; initial authorization is for no more than 4 doses4 doses

Continuation requires documentation of positive clinical response and ongoing signs/symptoms; continuation authorization for no more than 4 doses

Acute Graft-Versus-Host Disease (GVHD)

Covered when ALL of the following are met

GVHD initial therapy: Diagnosis of steroid-refractory acute GVHD; patient is receiving tocilizumab in combination with systemic corticosteroids or is intolerant to systemic corticosteroid therapy; initial authorization is for no more than 4 doses4 doses

Continuation requires documentation of positive clinical response and ongoing acute GVHD; continuation authorization for no more than 4 doses

Immune Checkpoint Inhibitor-Related Toxicities

Covered when ALL of the following are met

Immune checkpoint inhibitor-related toxicities: Recent receipt of checkpoint inhibitor therapy (e.g., pembrolizumab, nivolumab); diagnosis of severe immunotherapy-related inflammatory arthritis; no symptom improvement after 7 days of starting high-dose corticosteroids; history of failure, contraindication, or intolerance to infliximab; one of the following: patient is receiving tocilizumab in combination with systemic corticosteroids, or patient is intolerant to systemic corticosteroid therapy; authorization is for no more than 4 doses.4 doses

Rheumatoid arthritis — evidence and guideline context

Clinical evidence and guideline-informed considerations related to rheumatoid arthritis and use of tocilizumab

ACT-RAY trial design and outcomes: ACT-RAY randomized 556 patients to an add-on strategy (TCZ + MTX) or switch to TCZ alone with treat-to-target adjustments based on DAS28-ESR; radiographic and remission outcomes reported through 104 weeks.

Details of dosing and response-adapted csDMARD additions described in study methods.

Efficacy outcomes: By week 104, 76% completed year 2; 50.4% discontinued TCZ by week 104; 11.8% achieved total drug-free remission; add-on arm had higher drug-free remission than switch arm; adjusted mean change in Genant-modified Sharp Score was 0.35 (add-on) vs 0.95 (switch).

Flare rates after TCZ-free remission were high; most flares occurred within 52 weeks.

Guideline context: The 2021 ACR RA guideline recommends a treat-to-target approach, generally preferring methotrexate as the initial csDMARD for many patients; recommendations are classified as strong or conditional and should inform sequencing before biologic initiation.

Diagnosis-Specific Criteria (referenced)

Coverage is contingent on meeting Diagnosis-Specific Criteria for the indication and is updated to reference systemic targeted immunomodulators.

Diagnosis-Specific Criteria (placeholder): Full, detailed criteria per indication (RA, PJIA, SJIA, GCA) are maintained elsewhere in the policy—approval for any tocilizumab product is contingent on meeting those Diagnosis-Specific Criteria and lists of systemic targeted immunomodulators by indication have been updated.

Detailed nodes not present in provided chunks

Continuation Therapy

Criteria for continuation of therapy include:

Continuation: Prescriber must attest that the patient or caregiver cannot be trained or are physically unable to self-administer FDA-labeled self-administered tocilizumab; prescriber must submit an explanation.

From policy revision language requiring attestation for continuation of therapy.

Subcutaneous, self‑administered formulations of tocilizumab (Actemra and Tyenne) are obtained under the pharmacy benefit and are not covered under this medical benefit policy for intravenous infusion products.

The listed procedure and diagnosis codes are provided for reference only and do not by themselves imply that a service is covered or reimbursable. Benefit coverage and payment are determined by the member’s specific benefit plan document and applicable law.

Uses of tocilizumab that are considered experimental, investigational, or unproven may be excluded from coverage. Consult the member‑specific Certificate of Coverage and benefit plan document; applicable state mandates may supersede policy exclusions and permit coverage in certain circumstances.

The policy specifies that patients must not receive tocilizumab in combination with certain other systemic targeted immunomodulators for the same indication. Examples of agents updated in this revision include additions (e.g., Kevzara [sarilumab]) and removals of prior examples (see indication‑specific lists in the Diagnosis‑Specific Criteria).

FDA approval and labeled indications for tocilizumab products are provided for informational purposes only. FDA approval alone is not a basis for coverage; coverage decisions use the policy’s medical‑necessity criteria and member benefit language.

Billing and Diagnosis Codes

Covered HCPCS / J CodesHCPCSCovered

J3262	Injection, tocilizumab, 1 mg
Q5133	Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg
Q5135	Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg

Selected ICD-10 Diagnosis Codes (partial list)ICD-10

D89.810	Acute graft-versus-host disease
D89.831	Cytokine release syndrome, grade 1
D89.832	Cytokine release syndrome, grade 2
D89.833	Cytokine release syndrome, grade 3
D89.834	Cytokine release syndrome, grade 4
D89.835	Cytokine release syndrome, grade 5
D89.839	Cytokine release syndrome, grade unspecified
M05.00	Felty's syndrome, unspecified site
M05.011	Felty's syndrome, right shoulder
M05.012	Felty's syndrome, left shoulder

1–10 of 30

1/3

Applicable ICD-10 Codes — Extended ListICD-10

M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist

1–10 of 92

1/10

Provider Requirements, Prior Authorization, and Risk Notices

Prior Authorization

Prior Authorization Required and Dosing Limits

Prior authorization is required for all tocilizumab products. Documentation must include diagnosis, evidence of disease severity or treatment failure/intolerance, prior therapies, dosing per FDA label, and dosing calculations where applicable. Authorizations for most rheumatologic indications (e.g., RA, PJIA, SJIA, GCA) are limited to no more than 12 months for initial approvals; certain acute indications (CRS, acute GVHD, immune checkpoint inhibitor–related toxicities) are limited to no more than 4 doses for initial and continuation authorizations as specified in the Diagnosis-Specific Criteria.

Prior authorization required with supporting clinical documentation including diagnosis and prior treatment history.
Dosing must follow FDA-labeled dosing for the specific indication; submit dosing schedule and quantity requested.
Authorizations generally limited to ≤12 months for chronic rheumatologic indications; CRS/GVHD/checkpoint-toxicity approvals limited to ≤4 doses per authorization.

Background and Scope

Intravenous tocilizumab products (Actemra, Tofidence, Tyenne) are covered under the medical benefit for specified inflammatory and immune‑mediated conditions when the policy’s diagnosis‑specific medical‑necessity criteria are met. Tocilizumab is a recombinant humanized anti‑human interleukin‑6 (IL‑6) receptor monoclonal antibody that binds soluble and membrane IL‑6 receptors to inhibit IL‑6 signaling; IV formulations and their appropriate use are addressed in the medical benefit policy, while self‑administered subcutaneous formulations are obtained through the pharmacy benefit.

Definitions and Acronyms

Tocilizumab — policy definition

Policy definitionIn this policy 'tocilizumab' refers to all tocilizumab products (Actemra, Tofidence, Tyenne, and other U.S. FDA‑approved tocilizumab products).

ScopeApplies to intravenous tocilizumab products covered under the medical benefit; self‑administered subcutaneous formulations are obtained under the pharmacy benefit and not covered by this medical benefit policy.

Non‑preferred status noteAny U.S. FDA‑approved tocilizumab product not listed by name in the policy will be considered non‑preferred until reviewed by UnitedHealthcare.

Steroid‑refractory acute GVHD — definition

DefinitionAcute graft‑versus‑host disease (GVHD) that is steroid‑refractory — i.e., has not responded to systemic corticosteroid therapy or the patient is intolerant to systemic corticosteroids.

Policy Revision History

2026-03-01policy_revisionLatest

Policy revised to state any U.S. FDA‑approved tocilizumab product not listed by name will be considered non‑preferred until reviewed by UnitedHealthcare; approval for any tocilizumab product is made contingent on meeting the policy's Diagnosis‑Specific Criteria.

2026-03-01coverage_criteria_update

Updated examples of systemic targeted immunomodulators across indications; for GCA added Kevzara (sarilumab) and removed several agents (adalimumab, certolizumab, etanercept, baricitinib, golimumab, tofacitinib).

OpenPayer

Tocilizumab (Actemra, Tofidence, & Tyenne) Injection for Intravenous Infusion — Individual Exchange Medical Benefit Drug Policy

Coverage Criteria and Medical Necessity

Billing and Diagnosis Codes

Provider Requirements, Prior Authorization, and Risk Notices

Background and Scope

Definitions and Acronyms

Policy Revision History